Sun pharmaceutical industries limited: Healthy disclosure (House of Tatas)


Publications
(All)

Results 1-1 of 1 (Search time: 0.002 seconds).

Issue DateTitleSub-TitleAuthor(s)Journal NameVolume NumberIssue NumberPages
115-Jul-2019Sun pharmaceutical industries limited: Healthy disclosure (House of Tatas)-Ramachandran, J ; Ramesh, Savithran 

Abstract
Sun Pharmaceutical Industries Limited is the largest pharmaceutical company in India and one of the top five generic pharmaceutical companies in the world. For the past two decades, Sun Pharma has delivered high growth and profitability which has ensured that its stock has consistently traded at a premium above the industry average. However, for the past year, Sun Pharma has been at the receiving end of a spate of corporate governance issues, including whistleblower complaints to the stock market regulators, surrounding the company’s dealings with related parties and its disclosure practices. A study of the company’s recent challenges, in the backdrop of its spectacular growth and performance record till date, afford an excellent opportunity to examine the role and relevance of disclosure norms and regulations in enabling better corporate governance.
 
Keyword(s)
Pharmaceutical industry
Drug manufacturing
Healthcare industry
Project title
Sun pharmaceutical industries limited: Healthy disclosure (House of Tatas)
Project Coordinator
 
Status
Completed
Expected Completion
15-07-2019
 
Co-Investigator(s)